{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:54:49Z","timestamp":1785434089349,"version":"3.56.0"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Cefazolin breakpoints differ for the treatment of Enterobacterales urinary tract infections and systemic infections. A retrospective, exploratory cohort study of 148 patients found no difference in 30-day treatment outcomes based on the blood culture cefazolin minimum inhibitory concentration (\u22642 mcg\/mL versus 4\u201316 mcg\/mL) for patients transitioned to PO cephalosporins for the treatment of\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                      , or\n                      <jats:italic toggle=\"yes\">Proteus mirabilis<\/jats:italic>\n                      bacteremia secondary to a urinary source. Further research should confirm these findings.\u2003\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01357-25","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T14:02:11Z","timestamp":1771423331000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes with oral cephalosporins as definitive treatment of Enterobacterales bacteremia from a urinary source based on cefazolin minimum inhibitory concentration"],"prefix":"10.1128","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1885-8238","authenticated-orcid":true,"given":"Lauren","family":"Kobasuk","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Utah Health","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-5155","authenticated-orcid":false,"given":"Tamara","family":"Cisowska","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Utah Health","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Howard","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Utah Health","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gabriel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Utah Health","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaorong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah School of Medicine","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Imlay","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah School of Medicine","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Spivak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah School of Medicine","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2937-6397","authenticated-orcid":false,"given":"Kara","family":"Nazminia","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Pharmacy, University of Utah Health","place":["Salt Lake City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2018.6226"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.20166"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05498-2"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.12.007"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad657"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.435"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz364"},{"key":"e_1_3_2_9_2","unstructured":"CLSI. 2014. Performance standards for antimicrobial susceptibility testing. Twenty-fourth informational supplement. Wayne PA Clinical and Laboratory Standards Institute CLSI document M100-S24."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01357-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01357-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:02:19Z","timestamp":1775048539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01357-25"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Doernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"alternative-id":["10.1128\/aac.01357-25"],"URL":"https:\/\/doi.org\/10.1128\/aac.01357-25","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"2025-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01357-25"}}